Bioethics and PsoriasisHerbert B. Allen*, Rina Allawh, Lauren Ogrich, Neha Jariwala and Erum Ilyas
Department of Dermatology, Drexel University College of Medicine, USA
- *Corresponding Author:
- Herbert B. Allen
Department of Dermatology, Drexel University College of Medicine
219 N. Broad St, 4th floor, Philadelphia, PA 19107, United States
Fax: 215762 5570
E-mail: [email protected]
Received date: April 05, 2017; Accepted date: May 04, 2017; Published date: May 09, 2017
Citation: Allen HB, Allawh R, Ogrich L, Jariwala N, Ilyas E (2017) Bioethics and Psoriasis. J Clin Res Bioeth 8:304. doi: 10.4172/2155-9627.1000304
Copyright: © 2017 Allen HB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We have presented the clinical, epidemiological, microbiological, pathological, immunopathological, serological, and therapeutic studies showing how the streptococcus may be strongly linked to psoriasis. With this as background, we have presented three ethical arguments that are cogent for psoriasis. First, this microbial “pathogen” theory is both ignored and overlooked even with the abundance of evidence supporting it. That being the case, current treatments, consequently, are aimed not at the onset of the disease, but much later in the pathogenic cascade. Last, the continued use of “biologics” or costly immunosuppressives, which are not curative, presents bioethical challenges. We consider psoriasis a sequela of streptococcal infection similar to rheumatic fever, where treatment, at the earliest stages of the disease, has resulted in its disappearance.